THE NETHERLANDS— November 26, 2015 — Dr. Floris van Delft, Founder and Chief Scientific Officer of Synaffix will participate in a BioPharma Dealmakers webcast, sponsored in part by Synaffix, featuring two companies innovating antibody technology.
The webcast, part of the BioPharma Dealmakers series, is scheduled for:
11:00 am ET / 5:00 pm CET on December 16
The webcast will explore some of the technologies and companies ushering in the wave of next generation antibody technologies. Participants will learn about established approaches to improve antibody production and enhance the therapeutic index of ADCs — specifically proprietary approaches that have been shown to:
- Generate high-quality antibodies in large quantities
- Eliminate the formation of inclusion bodies in the antibody production
- Result in safer and more effective ADCs by attaching drugs to the naturally-occurring glycan anchor point, present on all antibodies
- Reduce ADC aggregation potential with a payload-enhancing linker technology
The webcast will include a round table discussion and a Q&A session to enable participants to contribute their own thoughts on this highly innovative field.
Dr. Floris van Delft, Ph.D., has been actively involved in the fields of click chemistry and protein conjugation technologies for many years. Other webcast participants include:
- Phil Barish, Vice President of Operations and R&D of AbSci
- Moderator : Gaspar Taroncher-Oldenburg, Ph.D. Dr. Taroncher-Oldenburg is an independent consultant and former managing editor of SciBX: Science-Business eXchange for Nature Publishing Group and the former scientific editor at Nature Biotechnology.
About the Webcast
BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.
Contact
Anthony DeBoer
Director, Business Development
Synaffix BV
+31 620 773 194
Prof. Floris van Delft – CSO
